Recently, Tebbe et al. has shown metformin could inhibit adipogenesis by inhibition of key adipogenesis regulating transcription factors (CEBPα, CEBPΔ, and SREBP1), and induced AMPK, and thereby could be a therapeutic option for ovarian cancer at an early stage, as it not only targets ovarian cancer, but also modulates the environmental milieu [75]. This evidence concerns the gene SREBF1 and ovarian cancer.